the aid library

LIST OPTIONS

Filter

8453

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Guidelines for developing inclusive water, sanitation and hygiene infrastructure

Arup; International Labour Organization ILO; UN Children's Fund UNICEF; UNOPS; WaterAid (2024) CC

Around the world, more than 2 billion people lack access to safely managed water, sanitation and hygiene services, with conflicts and climate change exacerbating the issue. Unsafe and insufficient WASH facilities, especially in rural and remote areas, can lead to increased health complications fo... more

UNAIDS Terminology Guidelines

UNAIDS (2024) CC

Language influences the way we think, how we perceive reality, and how we behave. With respect to HIV, language can embody stigma and discrimination, which impacts access to testing, acquisition of HIV, and engagement with treatment. Language plays a role in supporting respect and empowerment of ind... more

How To Add Deworming To Vitamin A Distribution

World Health Organization, UNICEF (2004)

Download (1142)

View PDF (3540)

Humanitarian Response in Violent Conflict
recommended

Catholic Relief Services CRS (2013)

A Toolbox of Conflict Sensitive Indicators. This toolbox adapts a sample of 15 indicators from the SPHERE Project's Humanitarian Charter and Minimum Standards in Humanitarian Response to be even more conflict sensitive while remaining practical and user-friendly

Download (818)

View PDF (1669)

A global brief on vector-borne diseases

World Health Organization (2014) C_WHO

With this World Health Day, WHO is drawing attention to a group of diseases that are spread by insects and other vectors, the heavy health and economic burdens they impose, and what needs to be done to reduce these burdens. Many of these diseases have been historically confined to distinct geographi... more

Download (838)

View PDF (1109)

Handbook for Disaster Assessment

Laura Ortíz, Omar D. Bello, Liudmila Ortega et al. Economic Commission for Latin America and the Caribbean (ECLAC), (2014)

This handbook reflects and updates the work that ECLAC has done in recent decades to establish a methodology for estimating the economic consequences of a disaster, and thus determine the financing required to rebuild and return the affected area to normal. The handbook's third edition strengthens p... more

Key messages for social mobilization and community engagement in intense transmission areas

World Health Organization (2014)

The messages should be used to inform, educate and engage different audience groups depending on their level of risk, vulnerability, presence in contact areas, care of patients with Ebola, or engagement or attendance of burials.

External Link

Rapid Risk Assessment of Acute Public Health Events
recommended

World Health Organization 2012 (2011) C_WHO

This manual has been developed to guide rapid risk assessment of acute public health risks from any type of hazard in response to requests from Member States of the World Health Organization (WHO). The manual is aimed primarily at national departments with health-protection responsibilities, Nationa... more

Download (765)

View PDF (1222)

WHO Global Epidemiological Surveillance Standards for Influenza

World Health Organization WHO (2014) C_WHO

Download (510)

View PDF (1256)

FAQs - Frequently asked questions on Antimicrobial resistance

World Health Organization WHO, Regional Office for South-East Asia (2011) C_WHO

Frequently asked questions on Antimicrobial resistance.

Download (2997)

View PDF (3161)

Standard Treatment Guidelines. Nigeria

Federal Ministry of Health Nigeria , World Health Organisation (WHO) (2008) C_WHO

Download (210)

View PDF (469)

Global data on visual impairments 2010

World Health Organization (WHO) (2012) C_WHO

Download (177)

View PDF (196)

World Drug Report 2019 Booklet 1 Executive summary / Policy implications

United Nations Office on Drug and Crime UNODOC (2022) C1

The World Drug Report 2022 is aimed not only at fostering greater international cooperation to counter the impact of the world drug problem on health, governance and security, but also, with its special insights, at assisting Member States in anticipating and address-ing threats from drug markets an... more

Download (240)

View PDF (239)

World Drug Report 2022 Booklet 2 Global Overview of Drug Demand and Supply

United Nations Office on Drug and Crime UNODC (2022) C1

Constituting the second part of the World Drug Report 2022, the present booklet contains an overview of the global demand for and supply of drugs. The first chapter of the booklet begins with the latest estimates of the number of people who use drugs, the distribution of those users by type of drug... more

Download (201)

View PDF (235)

World Drug Report 2019 Booklet 3 Drug market trends of Cannabis and Opioids

United Nations Office on Drug and Crime UNODC (2022) C2

This third booklet of the World Drug Report 2022 has a dual focus: opioids and cannabis. The first chapter of the booklet provides an overview of opioids as a group of substances and their patterns of non-medical use at the global level. It also reviews the latest trends in the global supply of opi... more

Download (203)

View PDF (277)

World Drug Report 2019 Booklet 5 Drugs and the environment

United Nations Office on Drug and Crime UNODC (2022) C2

The booklet starts with a general overview of how illicit drugs and the environment are linked within the bigger picture of the Sustainable Development Goals, climate change and environmental sustainability. It highlights direct and indirect linkages and gives examples of the significant local and i... more

Download (259)

View PDF (283)

Managing Yellow fever epidemics

World Health Organization WHO (2019) C_WHO

Download (199)

View PDF (188)

Climate Change and Health - Training Modules

World Health Organization (WHO) - Regional Office for South-East Asia (2015) C_WHO

Training Modules for climate change and Health - WHO

Guidelines for Management of Type 1 Diabetes

Indian Council of Medical Research (2022) CC2

The ICMR type 1 diabetes guidelines come at a time when the SARS-CoV-2 pandemic has disproportionately affected people with diabetes population, exposing them to a high risk for severe illness and mortality. Globally, diabetes was responsible for over fourmillion deaths in the year 2019. It was th... more

Humanitarian Response in Violent Conflict recommended

Rapid Risk Assessment of Acute Public Health Events recommended

Humanitarian Response in Violent Conflict
recommended

Rapid Risk Assessment of Acute Public Health Events
recommended